Sijmen de Vries, Pharming CEO
Former Novartis drug for ultra-rare disease gets speedy FDA review
Three years after paying a modest $20 million upfront to grab a late-stage rare disease drug from Novartis, Pharming has lined up a priority review …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
